首页> 美国卫生研究院文献>Cancer Science >Inactivating mutations and hypermethylation of the NKX2‐1/TTF‐1 gene in non‐terminal respiratory unit‐type lung adenocarcinomas
【2h】

Inactivating mutations and hypermethylation of the NKX2‐1/TTF‐1 gene in non‐terminal respiratory unit‐type lung adenocarcinomas

机译:非终末呼吸单位型肺腺癌中NKX2-1 / TTF-1基因的失活突变和甲基化过高

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The major driver mutations of lung cancer, EGFR mutations and EML4‐ALK fusion, are mainly detected in terminal respiratory unit (TRU)‐type lung adenocarcinomas, which typically show lepidic and/or papillary patterns, but are rarely associated with a solid or invasive mucinous morphology. In order to elucidate the key genetic events in non‐TRU‐type lung cancer, we carried out whole‐exome sequencing on 43 non‐TRU‐type lung adenocarcinomas based on morphology (17 acinar, nine solid, and two enteric adenocarcinomas, and 15 adenocarcinomas with a mucinous morphology). Our analysis identified mutations in TP53 (16/43, 37.2%), KRAS (13/43, 30.2%), and NKX2‐1/TTF‐1 (7/43; 16.3%) as the top three significantly mutated genes, while the EGFR mutation was rare (1/43, 2.3%) in this cohort. Eight NKX2‐1/TTF‐1 mutations (five frameshift, two nonsense, and one missense) were identified, with one case harboring two distinct NKX2‐1/TTF‐1 mutations (one missense and one frameshift). Functional assays with the NK2 homeobox 1 ( style="fixed-case">NKX2‐1)/thyroid transcription factor 1 ( style="fixed-case">TTF‐1) mutants revealed that none of them retain the activity as a transcriptional factor. Histologically, invasive mucinous adenocarcinomas accounted for most of the style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1 mutations (five cases), as well as one enteric and one acinar adenocarcinoma. Immunohistochemistry showed that the cohort was largely divided into style="fixed-case">TTF‐1‐postive/hepatocyte nuclear factor 4‐α ( style="fixed-case">HNF4‐α)‐negative and style="fixed-case">TTF‐1‐negative/ style="fixed-case">HNF4‐α‐positive groups. style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1 mutations were exclusively found in the latter, in which the gastrointestinal markers, mucin 5 style="fixed-case">AC and cytokeratin 20, were frequently expressed. Bisulfite sequencing revealed that the style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1 gene body was highly methylated in style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1‐negative cases, including those without the style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1 mutations. The genetic or epigenetic inactivation of style="fixed-case">NKX2‐1/ style="fixed-case">TTF‐1 may play an essential role in the development and aberrant differentiation of non‐ style="fixed-case">TRU‐type lung adenocarcinomas.
机译:肺癌的主要驱动基因突变,EGFR突变和EML4-ALK融合主要在终末呼吸单位(TRU)型肺腺癌中检测到,通常表现为鳞状和/或乳头状,但很少与实体或浸润相关粘液形态。为了阐明非TRU型肺癌的关键遗传事件,我们根据形态学对43例非TRU型肺腺癌进行了全基因组测序(17个腺泡,9个实体和2个肠腺癌,其中15个黏液状腺癌)。我们的分析确定了TP53(16/43,37.2%),KRAS(13/43,30.2%)和NKX2-1 / 1 / TTF-1(7/43; 16.3%)中的突变是前三个显着突变的基因,而在该队列中,EGFR突变很少见(1 / 43,2.3%)。鉴定出8个NKX2-1 / TTF-1突变(5个移码,2个无意义和1个错义),其中1个病例携带2个不同的NKX2-1 / 1 / TTF-1突变(1个错义和1个移码)。用NK2同源盒1( style =“ fixed-case”> NKX 2-1)/甲状腺转录因子1( style =“ fixed-case”> TTF -1)进行功能分析)突变体表明,它们都没有保留作为转录因子的活性。从组织学上讲,浸润性黏液腺癌占大多数 style =“ fixed-case”> NKX 2-1-1 style =“ fixed-case”> TTF -1突变(5例) ),以及一种肠溶性和一种腺泡性腺癌。免疫组织化学显示该队列主要分为 style =“ fixed-case”> TTF -1-阳性/肝细胞核因子4-α( style =“ fixed-case”> HNF 4-α)-阴性和 style =“ fixed-case”> TTF -1-阴性/ style =“ fixed-case”> HNF 4-α-阳性组。 style =“ fixed-case”> NKX 2-1-1 style =“ fixed-case”> TTF -1突变仅在后者中发现,其中胃肠道标志物,经常表达粘蛋白5 style =“ fixed-case”> AC 和细胞角蛋白20。亚硫酸氢盐测序显示, style =“ fixed-case”> NKX 2-1 / 1 style =“ fixed-case”> TTF -1基因体在 style中高度甲基化=“ fixed-case”> NKX 2-1 / 1 style =“ fixed-case”> TTF -1-1阴性案例,包括没有 style =“ fixed-case”的案例> NKX 2-1 / 1 style =“ fixed-case”> TTF -1突变。 style =“ fixed-case”> NKX 2-1 / 1 style =“ fixed-case”> TTF -1的遗传或表观遗传失活可能在发育中起重要作用和非 style =“ fixed-case”> TRU 型肺腺癌的异常分化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号